Corcept Therapeutics CORT
United StatesHealthcare · BiotechnologyUSD
141.00 USD (+17.9%)
5 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Corcept Therapeutics is a biopharmaceutical company that develops and commercializes drugs for the treatment of cortisol excess syndromes, with its main product approved for Cushing's syndrome.
Key points
from its scores- ✓Favourable backdrop8.7
- ✓Strong growth8.5
- ✓Good share-price trend8.5
- ✕Little or no dividend1.5
- ✕Demanding valuation2.7
AI analysis
bottom line, main risk, context and newsGrowth and net cash are attractive, but the current valuation already discounts future success that is not yet guaranteed.
Corcept Therapeutics shows exceptional growth (revenue +31.7%) and a gross margin of 98.3%, but its current valuation (P/E 265.78) is extremely demanding and depends on the pipeline meeting expectations, justifying a low valuation score (2.72) despite its solid financial health (8.41).
The main risk is the dependence on a single approved product and the regulatory and commercial uncertainty of its development pipeline, which may not materialize the growth that justifies its high multiple.
Context and risks
Corcept Therapeutics has no recent relevant news or material exposure to current macro factors. Its specialty oncology drug business does not depend on commodities, interest rates, or shipping routes, and its net cash balance sheet insulates it from tighter financial conditions. The inherent regulatory risk of the biotech sector is already reflected in its base risk profile.
Is Corcept Therapeutics stock cheap or expensive?
at the analysis dateOn P/E, it trades 894% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 265.8 | 26.7 | +894% |
| Price / book | 18.3 | 4.1 | +345% |
| Price / sales | 15.6 | 3.4 | +355% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 2.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 141.00 USD, +17.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 7.7 (sector 5.5), Growth 8.5 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 265.8
- Forward P/E
- 27.2
- EV / EBITDA
- 1,561.9
- Price / book
- 18.3
- Price / sales
- 15.6
- PEG
- 0.81
- Market cap
- 12.9B USD
- Enterprise value
- 12.6B USD
Profitability
- ROE
- 8.2%
- ROA
- 0.5%
- ROIC (approx.)
- 18.7%
- Gross margin
- 98.3%
- Operating margin
- 16.1%
- Net margin
- 6.6%
- Free cash flow
- 77.4M USD
- FCF yield
- 0.6%
- Cash conversion
- 957%
Solvency
- Total debt
- 9.4M USD
- Net debt
- −298.8M USD
- Cash
- 308.2M USD
- EBITDA
- 8.1M USD
- Net debt / EBITDA
- −36.96
- Debt / equity
- 1.33
- Current ratio
- 2.86
- Quick ratio
- 2.50
Growth
- Revenue growth
- +31.7%
- Earnings growth
- +24.1%
- EPS (TTM)
- 0.45 USD
- EPS (forward)
- 4.40 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.40
- Analyst consensus
- Buy (5)
- Target price
- 141.00 USD
- 52-week range
- 28.66 – 126.38
Recent news
All CORT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Corcept Therapeutics
Is Corcept Therapeutics stock cheap or expensive?
On P/E, it trades 894% above the Healthcare median. Valuation score: 2.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 141.00 USD, +17.9% versus the price. This is not investment advice.
What score does Corcept Therapeutics get on MeridIAn Screener?
It scores 6.5 out of 10, rank 515 of 2,130 (better than 72% of the companies analysed). Its strongest category is Risk & Context (8.7) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Corcept Therapeutics's P/E ratio?
Its P/E is 265.8: the share price equals 265.8 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 27.2.
How much is Corcept Therapeutics worth on the stock market?
Its market capitalisation is 12.9B USD and its enterprise value, debt included, is 12.6B USD.
How much debt does Corcept Therapeutics have?
It has more cash than debt: net cash of 298.8M USD.
Does Corcept Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Corcept Therapeutics stock performed over the last year?
It has risen 61.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 28.66 and 126.38 USD. Past performance does not guarantee future results.
What do analysts think of Corcept Therapeutics?
5 analysts cover it; their average recommendation is “Buy” and their average target is 141.00 USD (+17.9% versus the price). It is an estimate, not market data.